Agena Bioscience GmbH
Agena Bioscience - MassARRAY Colon Panel
Target: >200 clinically actionable somatic mutations in four principal oncogenes (KRAS, BRAF NRAS, PIK3CA)
Sample throughput: Up to 10 patient samples and 2 controls per plate
Sample amount:40ng DNA per sample
No of multiplexed PCR reactions: 8
Sensitivity: Detection and analysis of mutation frequencies as low as 5%
MassARRAY Dx Colon Panel is a CE-IVD approved set of clinically validated assays for cost-effective, accurate mutation screening to help you rapidly profile actionable somatic mutations in KRAS, BRAF, NRAS, and PIK3CA genes. The kit includes the required controls (wild-type and negative). The Panel is based upon clinical practice guidelines for diagnosis, treatment and follow-up for metastatic colorectal cancer recommended by ESMO.